Source comparison
Best BPC-157 Dosage Joint Support 2026: Protocol Comparison
Acute Tendon Injury 500 mcg Subcutaneous, single daily or split (250 mcg × 2) 4-6 weeks Maximal VEGFR2 activation during inflammatory/proliferative phases Preferred for post-injury angiogenesis; split dosing shows 20%+ faster healing in recent trials Chronic T
This comparison does not assign a generated winner or score.
- Acute Tendon Injury
- 500 mcg
- Subcutaneous, single daily or split (250 mcg × 2)
- 4-6 weeks
- Maximal VEGFR2 activation during inflammatory/proliferative phases
- Preferred for post-injury angiogenesis; split dosing shows 20%+ faster healing in recent trials
- Chronic Tendinopathy
- 250-350 mcg
- Subcutaneous, single daily
- 8-12 weeks
- Sustained collagen remodelling without excessive tissue turnover
- Lower dose minimizes receptor desensitization over extended protocols
- Post-Surgical Repair
- Peri-articular injection, daily
- 3-4 weeks
- Localized tissue concentration for scar tissue prevention
- Site-specific administration doubles local bioavailability vs distal injection
- Cartilage Degradation
- 300 mcg
- 10-16 weeks
- GAG synthesis upregulation and chondrocyte protection
- Moderate dose balances efficacy with cost over long research timelines
- Preventive/Maintenance
- 200-250 mcg
- Subcutaneous, 3-5× weekly
- Ongoing
- Low-grade tissue maintenance without tolerance development
- Mimics endogenous protective peptide levels; intermittent dosing prevents receptor downregulation